Goldman Sachs Group Inc. Grows Position in Capricor Therapeutics, Inc. $CAPR

Key Points

• Goldman Sachs Group Inc. increased its stake in Capricor Therapeutics by 39.5% in the 1st quarter, owning 411,141 shares valued at $3.9 million.
• Capricor Therapeutics reported a quarterly loss of ($0.57) earnings per share, missing analysts' expectations, and has a negative net margin of 181.71%.
• Despite recent stock volatility, several analysts maintain a buy rating on Capricor with a consensus target price of $22.56.

Goldman Sachs Group Inc. lifted its stake in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 39.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 411,141 shares of the biotechnology company's stock after acquiring an additional 116,373 shares during the quarter. Goldman Sachs Group Inc. owned about 0.90% of Capricor Therapeutics worth $3,902,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CAPR. Woodline Partners LP boosted its holdings in Capricor Therapeutics by 15.8% during the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company's stock worth $6,921,000 after buying an additional 99,384 shares in the last quarter. Octagon Capital Advisors LP acquired a new stake in shares of Capricor Therapeutics during the 1st quarter valued at $4,270,000. Northern Trust Corp lifted its position in shares of Capricor Therapeutics by 43.3% during the 4th quarter. Northern Trust Corp now owns 384,157 shares of the biotechnology company's stock valued at $5,301,000 after acquiring an additional 116,086 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Capricor Therapeutics by 938.9% during the 4th quarter. Bank of America Corp DE now owns 170,543 shares of the biotechnology company's stock valued at $2,353,000 after acquiring an additional 154,127 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its position in shares of Capricor Therapeutics by 392.7% during the fourth quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company's stock worth $2,334,000 after purchasing an additional 134,791 shares during the period. 21.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CAPR. Oppenheimer cut their target price on shares of Capricor Therapeutics from $43.00 to $22.00 and set an "outperform" rating on the stock in a research note on Monday, June 23rd. B. Riley initiated coverage on shares of Capricor Therapeutics in a report on Thursday, June 26th. They set a "buy" rating and a $21.00 price target on the stock. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Piper Sandler reaffirmed an "overweight" rating and issued a $20.00 price target on shares of Capricor Therapeutics in a research report on Friday, July 11th. Finally, Roth Capital decreased their price target on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating on the stock in a research report on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $22.56.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock traded up $0.32 during mid-day trading on Thursday, hitting $6.40. 885,201 shares of the company's stock traded hands, compared to its average volume of 1,076,396. Capricor Therapeutics, Inc. has a fifty-two week low of $4.92 and a fifty-two week high of $23.40. The stock has a market cap of $292.61 million, a price-to-earnings ratio of -3.90 and a beta of 0.73. The firm has a 50 day simple moving average of $7.03 and a two-hundred day simple moving average of $9.62.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. On average, research analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.